Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0AF6O
|
|||
| Drug Name |
Lorlatinib
|
|||
| Synonyms |
Loratinib; UNII-OSP71S83EU; Lorlatinib,PF-06463922; OSP71S83EU; lorlantinib; 4clj; 4cli; Lorlatinib [USAN:INN]; Lorlatinib (JAN/USAN/INN); PF06463922(Lorlatinib); GTPL7476; SCHEMBL15261807; EX-A828; MolPort-035-789-724; KS-00000T6C; 2641AH; ZINC98208524; s7536; MFCD28144520; BDBM50018830; AKOS027250753; DB12130; CS-39
Click to Show/Hide
|
|||
| Indication | Non-small-cell lung cancer [ICD-11: 2C25.Y; ICD-9: 162] | Approved | [1] | |
| Company |
Pfizer
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C21H19FN6O2
|
|||
| Canonical SMILES |
CC1C2=C(C=CC(=C2)F)C(=O)N(CC3=NN(C(=C3C4=CC(=C(N=C4)N)O1)C#N)C)C
|
|||
| InChI |
1S/C21H19FN6O2/c1-11-15-7-13(22)4-5-14(15)21(29)27(2)10-16-19(17(8-23)28(3)26-16)12-6-18(30-11)20(24)25-9-12/h4-7,9,11H,10H2,1-3H3,(H2,24,25)/t11-/m1/s1
|
|||
| InChIKey |
IIXWYSCJSQVBQM-LLVKDONJSA-N
|
|||
| CAS Number |
CAS 1454846-35-5
|
|||
| PubChem Compound ID | ||||
| ChEBI ID |
CHEBI:143117
|
|||
| ADReCS Drug ID | BADD_D02504 | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | ALK tyrosine kinase receptor (ALK) | Target Info | Inhibitor | [1] |
| Proto-oncogene c-Ros (ROS1) | Target Info | Inhibitor | [1] | |
| KEGG Pathway | Non-small cell lung cancer | |||
| WikiPathways | Differentiation Pathway | |||
| Spinal Cord Injury | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.